Tadalafil

Information about Tadalafil

Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction and pulmonary hypertension.

Liver safety of Tadalafil

Tadalafil therapy has not been associated with serum aminotransferase elevations, but has been linked to at least one published case of clinically apparent liver injury.

Mechanism of action of Tadalafil

Tadalafil (ta da' la fil) is a selective inhibitor of phosphodiesterase type 5 (PDE5), which mediates the breakdown of cyclic guanosine monophosphate (cGMP) inducing smooth muscle relaxation in the corpus cavernosum of the penis and in the pulmonary vasculature where this specific phosphodiesterase is found.

FDA approval information for Tadalafil

Tadalafil is effective in prolonging erection and was approved for treatment of erectile dysfunction in the United States in 2003 and for the treatment of [[pulmonary hypertension[[ and symptoms of ppbenign prostatic hypertrophy[[ in 2011.

Dosage and administration for Tadalafil

Tadalafil is available in tablets of 2.5, 5, 10 and 20 mg under the brand name of Cialis for erectile dysfunction and benign prostatic hyperplasia, and in 20 mg tablets under the brand name Adcirca for pulmonary hypertension. The recommended dose for erectile dysfunction is 10 mg as a single dose as needed approximately one hour before sexual activity. The dose can be increased or decreased based upon effect and tolerance, with a recommended maximum frequency of once daily and maximum dosage of 20 mg. The approved dose for pulmonary hypertension is 40 mg once daily.

Side effects of Tadalafil

Common side effects include dizziness, headache, flushing, hypotension, rhinitis and dyspepsia. Rare, but potentially serious adverse events inlucding vision and hearing loss, hypotension, cardiovascular events and priapism.

PDE 5 inhibitors

• Avanafil
• Sildenafil
• Tadalafil
• Vardenafil

• Dailymed label info on Tadalafil
• FDA Tadalafil

Tadalafil Resources
Latest articles Most recent articles Ongoing trials	Wikipedia